Related Experiment Videos
Bone marrow transplantation in thalassemia
G Lucarelli1, M Galimberti, P Polchi
1Divisione Ematologia e Centro Trapianto Midollo Osseo di Muraglia, Ospedale di Pesaro, Italy.
Hematology/Oncology Clinics of North America
|June 1, 1991
Summary
Bone marrow transplantation offers high survival rates for children with beta-homozygous thalassemia. Patient outcomes improve significantly when factors like hepatomegaly and portal fibrosis are absent before transplantation.
Area of Science:
- Hematology
- Pediatric Oncology
- Transplantation Medicine
Background:
- Beta-homozygous thalassemia is a severe inherited blood disorder requiring lifelong treatment.
- Hematopoietic stem cell transplantation (HSCT) is a potential cure but carries risks.
- Long-term outcomes and prognostic factors for HSCT in pediatric thalassemia patients require further elucidation.
Purpose of the Study:
- To evaluate the long-term survival and event-free survival rates following HSCT in pediatric patients with beta-homozygous thalassemia.
- To identify clinical factors associated with adverse outcomes after HSCT.
- To develop a risk stratification system to predict HSCT success in this patient population.
Main Methods:
- Retrospective analysis of 350 patients (1-19 years) undergoing HLA-identical sibling HSCT from 1983 onwards.
- High-dose busulfan and cyclophosphamide conditioning regimen used.
- Multivariate analysis performed on 172 consecutive patients treated since 1985 to identify prognostic factors.
Main Results:
- Overall survival and event-free survival rates stabilized at 82% and 75% respectively, around 1 year post-HSCT.
- Hepatomegaly, portal fibrosis, and inadequate chelation therapy were significantly associated with poorer survival.
- A risk classification system (Class 1: no risk factors, Class 3: all three risk factors) showed distinct outcomes: 3-year survival/EFS of 97%/94% (Class 1), 86%/83% (Class 2), and 58%/52% (Class 3).
Conclusions:
- HLA-identical sibling HSCT is a highly effective treatment for pediatric beta-homozygous thalassemia, offering substantial long-term survival.
- Pre-transplant clinical factors, including hepatomegaly, portal fibrosis, and chelation history, are critical predictors of HSCT success.
- Risk stratification based on these factors allows for better patient selection and management, particularly benefiting Class 1 patients.